- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors
Authors
Keywords
-
Journal
Immunotherapy
Volume 8, Issue 5, Pages 583-600
Publisher
Future Medicine Ltd
Online
2016-05-03
DOI
10.2217/imt-2015-0029
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference
- (2016) V. M. Hubbard-Lucey et al. Cancer Immunology Research
- Relevance of tumor-infiltrating lymphocytes in breast cancer
- (2015) Sathana Dushyanthen et al. BMC Medicine
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis
- (2015) Katia R M Leite et al. Diagnostic Pathology
- 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028
- (2015) P.A. Ott et al. EUROPEAN JOURNAL OF CANCER
- 22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma
- (2015) P. Nghiem et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
- (2015) Michael T. Barrett et al. Oncotarget
- PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
- (2015) R. W. Joseph et al. Cancer Immunology Research
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- CD8+ and FOXP3+ Tumor-Infiltrating T Cells Before and After Chemoradiotherapy for Rectal Cancer
- (2014) Eiji Shinto et al. ANNALS OF SURGICAL ONCOLOGY
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2014) S.J. Antonia et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
- (2014) S.J. Antonia et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
- (2013) B Goeppert et al. BRITISH JOURNAL OF CANCER
- Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
- (2013) Y Ino et al. BRITISH JOURNAL OF CANCER
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
- (2013) Raoul A. Droeser et al. EUROPEAN JOURNAL OF CANCER
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Immune infiltrates as predictive markers of survival in pancreatic cancer patients
- (2013) Maria Pia Protti et al. Frontiers in Physiology
- Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
- (2013) Sherene Loi OncoImmunology
- Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
- (2012) Esdy N. Rozali et al. Clinical & Developmental Immunology
- The Pancreas Cancer Microenvironment
- (2012) C. Feig et al. CLINICAL CANCER RESEARCH
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer
- (2012) Hiroaki Saito et al. JOURNAL OF SURGICAL ONCOLOGY
- Cancer classification using the Immunoscore: a worldwide task force
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- (2011) Makiko Ono et al. BREAST CANCER RESEARCH AND TREATMENT
- T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract
- (2011) Binfeng Lu et al. IMMUNOLOGIC RESEARCH
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
- (2010) Chuan-Yong Mu et al. MEDICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer
- (2009) Martin Loos et al. BMC CANCER
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
- (2009) Bastian Hoechst et al. HEPATOLOGY
- In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
- (2009) Franck Pagès et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion
- (2009) Yufu Ye et al. JOURNAL OF SURGICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now